5.92
-2.47%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jilin Jian Yisheng Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002566.SZ. It has been listed since 18 March 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥640.2m and net income of CN¥29.0m. At that date it held total assets of CN¥2.96bn and shareholders' equity of CN¥2.23bn.
Jilin Jian Yisheng Pharmaceutical Co., Ltd. engages in the research and development, production, and distribution of Chinese patent medicines. The company is headquartered in Tonghua, Jilin. The company went IPO on 2011-03-18. The Company’s main products consist of Shengmai injections, Zhenyuan capsules, Xinyue capsules, Qingkailing injections and Guifu Dihuang capsules, among others. The firm's products are applied in the treatment for heart cerebrovascular diseases and detoxification. The firm also provides health care products and cosmetics. The firm distributes its products within China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Mar 2011
- Employees
- 1,764
- Website
- yisheng-pharm.com ↗
Leadership
Pay as last reported
- Mr. Yisheng ZhangChairman of the Board, since 2000CN¥1.1m
- Mr. Xiaomin XueVice Chairman of the Board, General ManagerCN¥718,600
- Mr. Jiantao BiChief Financial Officer, Deputy General Manager, Director, since 2011CN¥538,900
- Mr. Wei MengChief Marketing Officer, Deputy General ManagerCN¥540,000
- Mr. Tiejun LiDeputy General Manager, Secretary of the Board, since 2021CN¥538,900
- Mr. Zhiqi LiangChief R&D Officer, Director
- Ms. He WangAssistant to Chairman of the Board, Director, since 2025
- Mr. Jianjun QuDirectorCN¥249,000
- Ms. Xiaole TongDirectorCN¥242,300
- Mr. Xin ZhangDirector
- Ms. Yan BiIndependent DirectorCN¥50,000
- Mr. Qibin ChenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has a strong presence in the Chinese pharmaceutical market with products like Shengmai injections and Zhenyuan capsules.
- Jilin Jian Yisheng Pharmaceutical Co Ltd employs 1,764 full-time employees, supporting its operations in Tonghua, Jilin.
- The company's IPO in March 2011 established a foundation for its public market presence.
Weaknesses
- The company's product portfolio is limited to specific Chinese patent medicines such as Qingkailing injections and Guifu Dihuang capsules.
- The firm distributes its products exclusively within the China market, restricting international expansion.
- The company's operations are concentrated in Tonghua, Jilin, limiting geographic diversification.
Opportunities
- The growing demand for Chinese patent medicines in the domestic health care sector presents an opportunity for expansion.
- The company can leverage its existing product lines like Xinyue capsules to enter new health care segments.
- Increasing focus on detoxification treatments aligns with the application of products such as Qingkailing injections.
Threats
- Competition from other pharmaceutical companies in the Chinese market poses a threat to market share.
- Regulatory changes in the Chinese health care sector could impact the production and distribution of Chinese patent medicines.
- The reliance on a single market (China) makes the company vulnerable to economic fluctuations within the country.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.